相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Removing T-cell epitopes with computational protein design
Chris King et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity
John E. Weldon et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Antibodies to watch in 2013 Mid-year update
Janice M. Reichert
MABS (2013)
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia
Robert J. Kreitman et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Frequency of Epitope-Specific Naive CD4+ T Cells Correlates with Immunodominance in the Human Memory Repertoire
William W. Kwok et al.
JOURNAL OF IMMUNOLOGY (2012)
Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A
Ronit Mazor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes
Wenhai Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2011)
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes
Masanori Onda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Peptide binding predictions for HLA DR, DP and DQ molecules
Peng Wang et al.
BMC BIOINFORMATICS (2010)
Molecular Determinants of T Cell Epitope Recognition to the Common Timothy Grass Allergen
Carla Oseroff et al.
JOURNAL OF IMMUNOLOGY (2010)
Aprotease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
John E. Weldon et al.
BLOOD (2009)
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
Robert J. Kreitman et al.
CLINICAL CANCER RESEARCH (2009)
A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach
Peng Wang et al.
PLOS COMPUTATIONAL BIOLOGY (2008)
Immunogenicity of protein therapeutics
Anne S. De Groot et al.
TRENDS IN IMMUNOLOGY (2007)
Phase I study of SS1P a recombinant anti-mesothelin immunotoxin given as a bolus IV infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2007)
Rationally engineered therapeutic proteins with reduced immunogenicity
S Tangri et al.
JOURNAL OF IMMUNOLOGY (2005)
Minimizing the immunogenicity of protein therapeutics
AJ Chirino et al.
DRUG DISCOVERY TODAY (2004)
Elimination of an immunodominant CD4+ T cell epitope in human IFN-β does not result in an in vivo response directed at the subdominant epitope
VP Yeung et al.
JOURNAL OF IMMUNOLOGY (2004)
Vaccination in humans generates broad T cell cytokine responses
SC De Rosa et al.
JOURNAL OF IMMUNOLOGY (2004)
Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity
JE Wedekind et al.
JOURNAL OF MOLECULAR BIOLOGY (2001)
分享论文
